CNS Pharmaceuticals, Inc.

Chief Business Officer, Dylan Wenke, Participates in Virtual Investor “What This Means” Segment Access the segment here HOUSTON, TX / ACCESS Newswire / September 1, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor “What This Means” Segment. Dylan Wenke, Chief Business Officer of CNS Pharmaceuticals, provided an update on its business development strategy as part of its broader transformation as the Company works to establish a pipeline focused on oncology or neurology with best in class potential. Mr. Wenke outlined the Company’s rigorous approach to evaluating potential opportunities, highlighting the scientific, clinical, regulatory, and commercial characteristics that define its in-licensing and acquisition targets. The conversation also gives investors insight into the Company’s business development process, from sourcing and initial diligence through comprehensive evaluation, along with the rationale behind its focus on oncology and neurology. Looking ahead, Mr. Wenke shared the Company’s near-term priorities, emphasizing continued execution of its business development strategy and the pursuit of opportunities that have the potential to create long-term shareholder value. The Virtual Investor “What This Means” segment is […]

Video webcast now available here HOUSTON, TX / ACCESS Newswire / August 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in the Virtual Investor “Why Now” on-demand conference. Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company’s strategic transformation that is being built on the strength of its newly assembled executive leadership team, enhanced financial position following its recent financing, and disciplined approach to evaluating differentiated assets. Mr. Levin emphasized the Company’s efforts to generate long-term growth and value creation as it executes the next phase of its strategy. The video webcast is now accessible for on-demand viewing here. JTC Team and Virtual Investor Co. are paid consultants to CNS Pharmaceuticals, Inc. JTC Team and Virtual Investor Co. are investor relations and corporate communications firms. Any content included in this release shall not be construed as an offer to purchase securities of CNS Pharmaceuticals, Inc. Interested parties are responsible for conducting their own due diligence and are encouraged to review the Company’s website and the SEC website for the latest information and […]

Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline HOUSTON, TX / ACCESS Newswire / August 12, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2026 and provided an update on the corporate strategy the company introduced in March 2026. “We are moving with speed and discipline to transform this company,” said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals. “In the second quarter, we significantly strengthened our balance sheet and added new expertise to our Board to enable us to build a differentiated, high-value pipeline of innovative therapies. We are executing with urgency and are confident that the actions we’ve taken this year strengthen CNS Pharmaceuticals ability to create meaningful value going forward.” Strategic and Corporate Highlights New corporate strategy in motion. Since announcing its strategic pivot in March 2026 beyond a singular focus on glioblastoma multiforme, the Company has been leveraging its executive team’s multi-functional experience across high-value therapeutic areas. […]

Access the segment here HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor “What This Means” Segment. Steve O’Loughlin, Chief Financial Officer of CNS Pharmaceuticals, discussed the Company’s recently completed oversubscribed $22.5 million financing in the virtual segment, addressing the factors that enabled the successful capital raise following its strategic reset and acquisition-focused transformation. The conversation explored investor reception to the Company’s evolving strategy, the significance of participation from leading healthcare-focused institutional investors and how the strengthened balance sheet enhances CNS Pharmaceuticals’ ability to pursue potential transformational opportunities. Mr. O’Loughlin also discussed the importance of institutional support and the Company’s long-term vision for creating shareholder value as it advances its next phase of growth. The Virtual Investor “What This Means” segment is available for on-demand viewing here. About CNS Pharmaceuticals, Inc.CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of […]

Access the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company’s recent $22.5 million financing, including its strategic pivot, progress made to date and how the capital positions CNS to identify and advance new assets aimed at driving long-term shareholder value. Additionally, Mr. Levin discussed the strategy for pipeline development and securing a new asset, key milestones investors should monitor to evaluate execution of the strategy and the Company’s broader growth outlook and investment thesis moving forward. The Virtual Investor CEO Connect segment is accessible here. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have […]

Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently announced corporate strategy Company actively evaluating multiple acquisition opportunities while advancing discussions to out-license its legacy glioblastoma multiforme programs, Berubicin and TPI-287 New executive leadership team assembled in the first quarter continues to demonstrate rapid execution against strategy HOUSTON, TX / ACCESS Newswire / May 14, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update highlighting the Company’s ongoing strategic transformation and execution progress. The first quarter of 2026 marked the beginning of a significant strategic shift for CNS Pharmaceuticals, including the appointment of a new Chief Executive Officer and executive leadership team, the launch of a new corporate strategy, the repositioning of the Company toward an acquisition-driven growth strategy focused on differentiated clinical-stage assets in neurology and oncology and the decision to seek out-licensing opportunities for its legacy glioblastoma multiforme programs, Berubicin and TPI-287. Subsequent to quarter end, CNS Pharmaceuticals completed a […]

The private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners Proceeds expected to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently announced corporate strategy HOUSTON, TX / ACCESS Newswire / May 4, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, announced today that it has entered into securities purchase agreements for a private placement financing that is expected to result in gross proceeds of approximately $22.5 million to the Company, before placement agent fees and offering expenses. The private placement includes participation from institutional healthcare investors, including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners. Pursuant to the terms of the securities purchase agreements, CNS is selling an aggregate of (i) 650,000 shares of its common stock (“Common Stock”) at a purchase price of $2.30 per share and (ii) pre-funded warrants to purchase 9,143,479 shares of Common Stock at a purchase price of $2.299 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share. The private […]

Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma’s largest and fastest-growing markets Strategic transformation driven by a comprehensive data analysis will enable new executive team to leverage decades of experience in these therapeutic areas Company pivoting from a singular focus on glioblastoma and will explore out-licensing of legacy assets berubicin and TPI 287 HOUSTON, TX / ACCESS Newswire / March 11, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (the “Company”), a biotechnology company focused on building a pipeline of innovative therapies in high-value neurology and oncology markets, today announced that it has launched a new corporate growth strategy designed to build a high-value pipeline in neurology and oncology. The strategy is being led by the newly formed executive team with deep experience across neurology, oncology and rare disease drug development. The team is driving a disciplined, data-driven approach to identify, acquire and advance differentiated therapeutic programs capable of delivering meaningful clinical and commercial value. CNS Pharmaceuticals conducted an independent, rigorous evaluation of its existing pipeline, development priorities and broader market opportunities as part of a comprehensive strategic review. The process incorporated clinical probability-of-success modeling, competitive landscape assessments, regulatory pathway evaluations […]

Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNS Newly formed executive team is committed to execution and company evolution focused on patient and stakeholder value HOUSTON, TX / ACCESS Newswire / March 2, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer. Dr. Kelley brings more than two decades of global leadership experience across clinical development, translational medicine and regulatory strategy in oncology, rare diseases, CNS and medical devices. She has successfully led Phase 1-3 clinical programs and supported regulatory approvals across the United States, Europe, China, and Japan, and is widely recognized for building high-performing medical organizations and delivering successful regulatory and commercial outcomes. “The depth, breadth and experience that Dr. Kelley brings to the Company will be instrumental as we prioritize and strategically build our pipeline. She is an exceptional medical leader with deep expertise in oncology, CNS and rare disease drug development and will play a key role in […]

New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional Expertise to Support Company Growth and Value Creation HOUSTON, TX / ACCESS Newswire / February 17, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the Company’s recently appointed President and Chief Executive officer, Rami Levin, in close alignment with the Board of Directors, has recruited key members to his new executive team. These new appointments, which will be effective March 2, 2026, will help drive the Company’s evolution. The Company announced the following appointments: Steven O’Loughlin as Chief Financial Officer Eric Faulkner, MSc, MBA, as Chief Technology Officer Dylan Wenke, MBA, as Chief Business Officer “These appointments are not incremental. They are expected to be transformational,” said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals. “We are focused on building CNS Pharmaceuticals into a strategic, forward-looking, execution-driven biotechnology company. With this team in place, I believe we significantly elevate our ability to make high-quality decisions, engage stakeholders with credibility, allocate capital with discipline and advance our […]